CVRx (CVRX) Stock Forecast & Price Target

CVRx Inc has demonstrated significant growth in its operational capacity, having increased the number of active implanting centers to 240, representing a sequential rise of 13 centers. While total operating expenses rose approximately 8% year-over-year to $25.8 million, this increase was primarily attributed to a larger investment in selling, general, and administrative expenses, which grew about 11% year-over-year. The company’s focus on expanding its market presence in the USA and enhancing its commercial infrastructure could indicate a strong foundation for future revenue growth through its proprietary Barostim technology.

CVRx Inc has demonstrated a reduction in its FY25 revenue guidance, with the new estimate set between $55.0 million and $57.0 million, indicating only modest growth of approximately 7-11% year-over-year. The company's gross margin for 2Q25 remained stagnant at 84%, failing to show improvement despite operational efforts. Furthermore, the 2026 revenue estimate has also been revised downward from $74.1 million to $67.6 million, suggesting a slowdown in projected growth, particularly in the U.S. market.